Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL1664733 | 0.98 | EPHX1 (0.45) | EPHX1ALDH1A1EBPSIGMAR1TDP1 | |
| 1-Hexanol SCHEMBL28200638 | 0.90 | ALDH1A1 (0.48) | EPHX1ALDH1A1EBPSIGMAR1TDP1 | |
| 1-Pentanol SCHEMBL28201262 | 0.88 | SMN1; SMN2 (0.46) | EPHX1ALDH1A1TSHRSMN1; SMN2RAB9A | |
| Propane SCHEMBL29260697 | 0.85 | — | — | |
| Butyl Alcohol SCHEMBL28856285 | 0.85 | ALDH1A1 (0.44) | EPHX1ALDH1A1TSHRSMN1; SMN2RAB9A | |
| SCHEMBL28596158 | 0.85 | EPHX1 (0.35) | EPHX1ALDH1A1SMN1; SMN2RAB9ACYP1A2 | |
| Bromide SCHEMBL28886830 | 0.84 | EPHX1 (0.34) | EPHX1SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL10067 | 0.83 | — | — | |
| SCHEMBL2473867 | 0.83 | NOS2 (0.35) | — | |
| SCHEMBL31673148 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763225-B | Preparation method of anhydrous tris (pentafluorophenyl) borane | 卫星化学股份有限公司 | 2023-02-10 | — | — | CN | claimed |
| CN-111763225-A | Preparation method of anhydrous tris (pentafluorophenyl) borane | 浙江卫星石化股份有限公司 | 2020-10-13 | — | — | CN | claimed |
| WO-2024136884-A1 | SALTS INCLUDING CRYSTALLINE SALTS OF 25-HYDROXY-CHOLEST-5-EN-3-SULFATE AND METHODS FOR PREPARING SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138203-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, FORMULATIONS THEREOF AND METHODS FOR PREPARING, AND MEDICAL USES OF SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240173328-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4359420-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE AND METHODS FOR PREPARING, AND USES OF, SAME | Durect Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11918584-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4234546-A2 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2307393-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009155386-A1 | A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 | ABBOTT LABORATORIES (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885ALDH1A1 2858/4885EBP 145/4885 |
| US-20240173328-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | EPHX1 2471/4885ALDH1A1 2241/4885EBP 3310/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885ALDH1A1 2858/4885EBP 145/4885 |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | EPHX1 2316/4885ALDH1A1 4088/4885EBP 3282/4885 |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | EPHX1 3126/4885ALDH1A1 4395/4885EBP 3839/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885ALDH1A1 2858/4885EBP 145/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885ALDH1A1 2858/4885EBP 145/4885 |
| US-11918584-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | KRAS, NRAS, HRAS | EPHX1 3017/4885ALDH1A1 2233/4885EBP 3273/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885ALDH1A1 2858/4885EBP 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.